poisar

Stocks · News reference

Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BIIB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

    Denali Therapeutics (DNLI) shares gained 7.8% after reporting Q3 results that beat expectations, with Avlayah revenues reaching $17.8 million and nearly fivefold growth from the previous quarter. The company expects Q4 revenues between $30-32 million and plans multiple 2027 pipeline readouts including an accelerated approval filing for zafinofusp alfa. Despite strong commercial uptake and $1.01 billion in cash, the stock carries a Zacks Rank #3 (Hold) rating due to pipeline setbacks and the loss of Takeda as a partner.

    DNLIBIIBTAK
  3. Delveinsight

    BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight

    The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.

    LLYNVSRHHBYONCMRK